Across TCGA pan-cancer cohorts, BLVRB Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated BLVRB data layer compared with 20 for mass-spec protein and 6 for mass-spec protein.
The strongest signal is observed in esophageal carcinoma (ESCA), where higher BLVRB Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated BLVRB expression acts as an unfavorable survival marker.
ESCA are the cancer types where BLVRB Mutation most reproducibly stratifies survival.